Profile data is unavailable for this security.
About the company
GlucoTrack, Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is developing an implantable continuous glucose monitoring (CGM) for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients. It is developing an implantable continuous blood glucose monitor (CBGM). This product is designed to have an approximately two-year implant longevity without the requirement for any wearable components. The CBGM utilizes an intravascular approach, in which the device is implanted subcutaneously and connected to a lead that is placed directly into a blood vessel. This facilitates continuous blood glucose measurements with zero lag time. The Company is also developing the Glucotrack CBGM a companion mobile application and a cloud-based solution to provide real time, data-driven personalized tools to effectively help a user manage their diabetes and assist healthcare providers with making treatment decisions.
- Revenue in USD (TTM)0.00
- Net income in USD-8.74m
- Incorporated2010
- Employees6.00
- LocationGlucoTrack Inc301 Rte 17 North, Ste. 800RUTHERFORD 07070United StatesUSA
- Phone+1 (201) 842-7715
- Fax+1 (302) 655-5049
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marizyme Inc | 549.70k | -69.02m | 12.26m | 11.00 | -- | -- | -- | 22.30 | -1.42 | -1.42 | 0.0081 | -0.0822 | 0.0184 | 1.65 | 14.06 | 49,972.73 | -230.68 | -59.02 | -531.63 | -64.47 | 71.17 | 70.38 | -12,555.69 | -9,435.92 | 0.0279 | -0.5837 | 1.92 | -- | 176.59 | 99.98 | -71.22 | -- | -- | -- |
| BioRestorative Therapies Inc | 149.50k | -10.95m | 12.52m | 11.00 | -- | 0.8644 | -- | 83.77 | -2.34 | -2.34 | 0.0302 | 2.14 | 0.0093 | -- | 5.86 | 13,590.91 | -68.40 | -199.86 | -77.93 | -342.60 | -- | -- | -7,327.44 | -19,887.03 | -- | -- | 0.00 | -- | 21.70 | 5.61 | 22.06 | -- | 67.77 | -- |
| Cell MedX Corp | 70.00 | -96.91k | 12.78m | 0.00 | -- | -- | -- | 182,588.10 | -0.0029 | -0.0029 | 0.00 | -0.0024 | 0.0015 | -- | -- | -- | -202.28 | -792.55 | -- | -- | -685.71 | -- | -138,442.90 | -3,681.84 | -- | -3.17 | -- | -- | -54.53 | -- | 29.01 | -- | -- | -- |
| Nanopharmaceutics Inc | 1.01m | -549.47k | 12.84m | 50.00 | -- | -- | -- | 12.72 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| Check Cap Ltd | 0.00 | -17.57m | 12.87m | 85.00 | -- | 0.5434 | -- | -- | -3.00 | -3.00 | 0.00 | 4.05 | 0.00 | -- | -- | -- | -49.87 | -54.23 | -53.46 | -60.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.06 | -- | -2.46 | -- |
| Guardion Health Sciences Inc | 12.06m | -5.12m | 12.95m | 9.00 | -- | 3.79 | -- | 1.07 | -4.00 | -4.00 | 9.49 | 2.66 | 0.9718 | 2.63 | 5.96 | 1,340,280.00 | -41.26 | -77.90 | -47.92 | -86.55 | 43.43 | 42.45 | -42.46 | -176.93 | 6.49 | -4.24 | 0.00 | -- | 10.85 | 67.03 | 101.00 | -- | -58.56 | -- |
| Organovo Holdings Inc | 109.00k | -14.67m | 13.02m | 12.00 | -- | 2.53 | -- | 119.43 | -1.62 | -1.62 | 0.0119 | 0.3573 | 0.0082 | -- | 1.18 | 5,450.00 | -110.05 | -54.25 | -138.86 | -58.42 | -- | -- | -13,459.63 | -1,890.16 | 1.96 | -- | 0.00 | -- | -70.54 | -48.78 | 15.00 | -- | -11.87 | -- |
| GlucoTrack Inc | 0.00 | -8.74m | 13.15m | 6.00 | -- | 34.16 | -- | -- | -1.87 | -1.87 | 0.00 | 0.0703 | 0.00 | -- | -- | 0.00 | -520.58 | -94.01 | -2,110.63 | -142.35 | -- | -- | -- | -10,447.96 | -- | -- | 0.3415 | -- | -- | -- | -60.02 | -- | -- | -- |
| Pieris Pharmaceuticals Inc | 40.93m | -16.25m | 13.32m | 46.00 | -- | 0.5681 | -- | 0.3255 | -12.74 | -12.74 | 34.05 | 17.76 | 0.7324 | -- | 28.25 | 889,717.40 | -29.09 | -28.41 | -52.98 | -39.69 | -- | -- | -39.71 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 13.55m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| Cardio Diagnostics Holdings Inc | 33.00k | -11.51m | 13.57m | 7.00 | -- | 4.26 | -- | 411.09 | -0.8257 | -0.8257 | 0.0021 | 0.1404 | 0.0051 | -- | -- | 4,714.29 | -178.70 | -- | -325.81 | -- | -- | -- | -34,872.12 | -- | -- | -4.84 | 0.0715 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
| CV Sciences Inc | 15.86m | -3.23m | 13.65m | 42.00 | -- | 5.78 | -- | 0.8605 | -0.0207 | -0.0207 | 0.1012 | 0.0145 | 1.59 | 1.42 | 27.25 | 377,571.40 | -32.43 | -43.42 | -83.71 | -77.75 | 45.13 | 51.81 | -20.38 | -45.68 | 0.2677 | -13.32 | 0.0472 | -- | -1.24 | -19.80 | 133.96 | -20.87 | -- | -- |
| Nexgel Inc | 4.74m | -3.20m | 14.01m | 19.00 | -- | 2.93 | -- | 2.96 | -0.5535 | -0.5535 | 0.8208 | 0.7688 | 0.4428 | 3.24 | 8.46 | 249,263.20 | -30.72 | -44.61 | -39.92 | -56.19 | 20.14 | 5.02 | -69.38 | -180.98 | 1.41 | -- | 0.1819 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
Data as of Jun 14 2024. Currency figures normalised to GlucoTrack Inc's reporting currency: US Dollar USD
2.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sabby Management LLCas of 31 Mar 2024 | 122.93k | 2.24% |
| Alerus Financial, NA (Private Banking)as of 31 Mar 2024 | 13.86k | 0.25% |
| Virtue Capital Management LLCas of 31 Mar 2024 | 6.00k | 0.11% |
| Accurate Wealth Management LLCas of 31 Mar 2024 | 4.42k | 0.08% |
| Citadel Securities LLCas of 31 Mar 2024 | 4.41k | 0.08% |
| G1 Execution Services LLCas of 31 Mar 2024 | 2.74k | 0.05% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 2.60k | 0.05% |
| Boston Financial Management LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| UBS Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| Two Sigma Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
